Novogene Co Ltd
SSE:688315

Watchlist Manager
Novogene Co Ltd Logo
Novogene Co Ltd
SSE:688315
Watchlist
Price: 12.74 CNY -7.28% Market Closed
Market Cap: 5.3B CNY
Have any thoughts about
Novogene Co Ltd?
Write Note

Novogene Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Novogene Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Novogene Co Ltd
SSE:688315
Income from Continuing Operations
ÂĄ183.2m
CAGR 3-Years
75%
CAGR 5-Years
13%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Income from Continuing Operations
ÂĄ8.6B
CAGR 3-Years
30%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
15%
CAGR 5-Years
38%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Income from Continuing Operations
ÂĄ3B
CAGR 3-Years
2%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Income from Continuing Operations
ÂĄ1B
CAGR 3-Years
-29%
CAGR 5-Years
7%
CAGR 10-Years
24%
W
WuXi XDC Cayman Inc
HKEX:2268
Income from Continuing Operations
ÂĄ283.5m
CAGR 3-Years
121%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novogene Co Ltd
Glance View

Market Cap
5.3B CNY
Industry
Life Sciences Tools & Services

Novogene Co., Ltd. engages in the provision of genomic services and solutions. The company is headquartered in Beijing, Beijing and currently employs 2,284 full-time employees. The company went IPO on 2021-04-13. The firm mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. At the same time, based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The firm's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The firm conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.68 CNY
Undervaluation 44%
Intrinsic Value
Price

See Also

What is Novogene Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
183.2m CNY

Based on the financial report for Dec 31, 2023, Novogene Co Ltd's Income from Continuing Operations amounts to 183.2m CNY.

What is Novogene Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
13%

Over the last year, the Income from Continuing Operations growth was 1%. The average annual Income from Continuing Operations growth rates for Novogene Co Ltd have been 75% over the past three years , 13% over the past five years .

Back to Top